General Pharmacology Practice Questions

Q: Which opioid is MOST commonly available and used as a nasal spray formulation for acute pain management?

Butorphanol. ***Butorphanol*** - **Butorphanol** is a synthetic opioid agonist-antagonist that is **most commonly** available as a **nasal spray** formulation (Stadol NS), primarily used for the treatment of **migraines** and **moderate to severe acute pain**. - Its **intranasal formulation** allows for rapid absorption and quick onset of action, making it the **most widely prescribed** nasal opioid for acute pain relief. - It has been marketed as a nasal spray for decades and remains the **gold standard** intranasal opioid analgesic. *Tramadol* - **Tramadol** is an opioid analgesic typically available in **oral** (tablets, capsules) and **injectable** forms. - While some research has explored intranasal formulations, it is **not commercially available** as a nasal spray for routine pain management. *Codeine* - **Codeine** is a prodrug metabolized to morphine and is widely available in **oral formulations** (tablets, syrups) and sometimes in injectable forms. - It is **not available** as a nasal spray for pain relief. *Buprenorphine* - **Buprenorphine** is a partial opioid agonist available in various formulations including **sublingual tablets**, **transdermal patches**, and **injectable solutions**. - While buprenorphine **nasal spray formulations do exist** (primarily for opioid use disorder treatment), **butorphanol** remains the **most commonly used and prescribed** intranasal opioid specifically for **acute pain management**.

Q: Which of the following is not an alkaloid?

Aspirin. ***Aspirin*** - **Aspirin** (acetylsalicylic acid) is a synthetic derivative of **salicylic acid**, a non-alkaloid compound. - Alkaloids are generally naturally occurring organic compounds containing **nitrogen atoms** in a heterocyclic ring system, while aspirin does not fit this chemical structure definition. *Morphine* - **Morphine** is a naturally occurring **alkaloid** derived from the opium poppy [1]. - It contains a **nitrogen atom** within a heterocyclic ring, making it a classic example of an alkaloid [1]. *Physostigmine* - **Physostigmine** is an **alkaloid** obtained from the Calabar bean plant. - It contains a **nitrogen atom** as part of its molecular structure and is classified as a cholinergic alkaloid. *Atropine* - **Atropine** is a naturally occurring **alkaloid** found in plants of the Solanaceae family, like deadly nightshade [2], [3]. - Its chemical structure includes a **nitrogen atom** within a heterocyclic ring system, consistent with the definition of an alkaloid [2].

Q: Which vitamin is known to inhibit wound healing?

Vitamin E. ***Vitamin E*** - **High doses** or **supraphysiologic levels** of vitamin E may potentially **impair wound healing** due to anticoagulant effects and possible interference with platelet function. - Excessive vitamin E supplementation (above recommended doses) can increase **bleeding risk** at surgical and wound sites, potentially delaying healing. - **Note:** Physiologic doses of vitamin E do not inhibit wound healing; this refers specifically to excessive supplementation. *Vitamin A* - **Vitamin A** plays a crucial role in wound healing by promoting **epithelial cell differentiation** and collagen synthesis. - It aids in **immune function** and inflammation modulation, both vital for effective wound repair. - Can even counteract steroid-induced impairment of wound healing. *Vitamin C* - **Vitamin C** is essential for **collagen synthesis** and cross-linking, which provides tensile strength to healing wounds. - Acts as an **antioxidant** and is vital for immune function, supporting tissue repair processes. - Deficiency leads to impaired wound healing (scurvy). *Vitamin B complex* - **B vitamins**, particularly **B1 (thiamine)**, **B5 (pantothenic acid)**, and **B6 (pyridoxine)**, are important cofactors in metabolic processes crucial for cell proliferation and tissue repair. - They contribute to energy production and synthesis of proteins and DNA needed for wound healing.

Q: The H3 receptor agonist exhibits all of the following actions except:

Increase in H2 mediated gastric secretion. ***Increase in H2 mediated gastric secretion*** - H3 receptor agonists inhibit the release of **histamine** from presynaptic terminals. - Less histamine means **reduced stimulation of parietal cells** (which are H2-mediated) and a decrease, not an increase, in gastric acid secretion. - H3 agonists would therefore **reduce, not increase**, H2-mediated gastric secretion. *Inhibition of H1 receptors induced wakefulness* - H3 receptor agonists reduce the release of histamine from histaminergic neurons, leading to **decreased H1 receptor activation** in the brain. - This diminished H1 activation contributes to a **reduction in wakefulness** and promotion of sleep. - This is a **true action** of H3 agonists. *Inhibition of H1 mediated bronchoconstriction* - By decreasing histamine release, H3 receptor agonists lower the amount of histamine available to bind to H1 receptors on **bronchial smooth muscle**. - This results in a **reduction in H1-mediated bronchoconstriction**. - This is a **true action** of H3 agonists. *Negative chronotropic effect on atria* - H3 receptors are present in the heart, and their activation can lead to a **reduction in heart rate** (negative chronotropic effect). - This effect is mediated through the **inhibition of histamine release locally** or directly on cardiac cells. - This is a **true action** of H3 agonists.

Q: What is the primary mechanism by which steroids exert their anti-inflammatory action?

Phospholipase A2. ***Phospholipase A2*** - Steroids exert their primary anti-inflammatory action by inducing the synthesis of **lipocortin-1 (annexin-1)**, which then inhibits **phospholipase A2 (PLA2)**, an enzyme crucial for the release of **arachidonic acid** from cell membrane phospholipids. - By blocking PLA2, steroids prevent the formation of all subsequent inflammatory mediators derived from arachidonic acid, including **prostaglandins**, **leukotrienes**, and **thromboxanes**. - This represents the most **upstream** mechanism of steroid anti-inflammatory action, affecting multiple downstream pathways simultaneously. *Cyclooxygenase* - **Cyclooxygenase (COX)** enzymes, specifically COX-1 and COX-2, are responsible for converting arachidonic acid into **prostaglandins** and **thromboxanes**. - While steroids ultimately reduce COX activity by limiting substrate availability, their direct and primary inhibition is not on COX itself but at an earlier step in the inflammatory cascade. *Lipoxygenase* - The **lipoxygenase (LOX)** pathway converts arachidonic acid into **leukotrienes**, which are potent mediators of inflammation, particularly in asthma and allergic reactions. - Steroids do inhibit the formation of leukotrienes indirectly by blocking their precursor, arachidonic acid, but their direct target is not LOX itself. *Myeloperoxidase* - **Myeloperoxidase** is an enzyme found primarily in **neutrophils** and macrophages, playing a role in oxidative stress and microbial killing by producing hypochlorous acid (bleach). - While steroids can modulate immune cell function, their direct anti-inflammatory mechanism is not through the inhibition of myeloperoxidase activity.

Q: At which phase of a drug trial is permission from the DCGI required?

Phase 1. ***Phase 1*** - **Permission from the Drugs Controller General of India (DCGI)** is **first required** to initiate **Phase 1 clinical trials** in India. - This permission is obtained through submission of an **Investigational New Drug (IND)** application to DCGI. - Phase 1 trials involve the **first-in-human** studies to assess **safety, tolerability, pharmacokinetics**, and **pharmacodynamics** in a small group of healthy volunteers or patients. - **No clinical trial can begin in India without DCGI approval**, making Phase 1 the critical regulatory checkpoint for initial permission. *Phase 2* - While Phase 2 trials also require DCGI oversight and approval to proceed from Phase 1, the question asks when permission is **required**, which is at the **initial entry point** (Phase 1). - Phase 2 focuses on evaluating **efficacy** and further assessing **safety** in a larger group of patients with the target disease. *Phase 3* - Phase 3 trials involve large-scale studies to confirm **efficacy**, monitor **adverse reactions**, and compare with standard treatments. - These trials proceed under the original DCGI approval framework established at Phase 1, with continued regulatory oversight. *Phase 4* - Phase 4 trials are **post-marketing surveillance** studies conducted after the drug has received marketing approval. - These are conducted under different regulatory guidelines for pharmacovigilance and long-term safety monitoring.

Q: Therapeutic index of a drug is an indicator of its:

Safety Profile. ***Safety Profile*** - The **therapeutic index (TI)** is a ratio that compares the dose of a drug that produces a **toxic effect** to the dose that produces a **therapeutically desired effect**. - A higher therapeutic index generally indicates a **safer drug**, as it means a larger dose is required to cause toxic effects compared to the therapeutic dose. *Effectiveness* - While related to efficacy, effectiveness usually refers to how well a drug works in **real-world clinical practice**, not directly measured by the therapeutic index. - The therapeutic index focuses on the **margin between efficacy and toxicity**, rather than just the degree of positive response. *Adverse Effects* - The **therapeutic index** considers the toxic dose, which leads to adverse effects, but it's a measure of the **margin of safety**, not just the presence or absence of adverse effects. - It quantifies the **risk of adverse effects** relative to the therapeutic benefit, rather than simply listing or describing them. *Therapeutic Effect* - The **therapeutic index** incorporates the dose required for a therapeutic effect, but its primary purpose is to assess the **risk of toxicity** in relation to that therapeutic effect. - It's a measure of the **balance between benefit and harm**, not solely the therapeutic benefit itself.

Q: Which of the following is NOT a primary function of histamine antagonists as a drug class?

Antivertigo. ***Antivertigo*** - While some first-generation **H1-antihistamines** like dimenhydrinate and meclizine have **antivertigo** properties due to their anticholinergic and sedative effects, this is a specific *effect* of certain histamine antagonists, not a general *function* that all antagonists exhibit. - The question asks for an exception to the *general functions* of histamine antagonists. **Antivertigo** is not a primary, universal effect of histamine antagonism in the way the other options describe. *Antipruritic* - **H1-antihistamines** block the action of **histamine** on **H1 receptors**, which are involved in mediating itching (**pruritus**). - This is a common and primary function of **H1-antagonists** in treating allergic reactions and skin conditions. *Sedation* - First-generation **H1-antihistamines** readily cross the **blood-brain barrier** and block **H1 receptors** in the brain, leading to drowsiness and **sedation**. - This is a well-known side effect and, in some cases, a therapeutic use of these drugs. *Inhibition of gastric acid secretion* - **H2-antihistamines** (e.g., ranitidine, cimetidine) specifically block **histamine H2 receptors** on **parietal cells** in the stomach, thereby reducing **gastric acid secretion**. - This is a primary function of a distinct class of histamine antagonists used to treat acid-related disorders.

Question 1

Which opioid is MOST commonly available and used as a nasal spray formulation for acute pain management?

Accepted Answer

Butorphanol

Answer

Tramadol

Answer

Buprenorphine

Answer

Codeine

Question 2

Which of the following statements is true regarding a fixed-dose combination of drugs?

Accepted Answer

The adverse effect of one drug may be mitigated by the other drug.

Answer

The dose of one drug can be adjusted independently.

Answer

Adverse effects can be attributed solely to one drug.

Answer

Combining two drugs with different pharmacokinetics is straightforward.

Question 3

Which of the following statements about orphan drugs is true?

Accepted Answer

Diagnosis, prevention, or treatment of rare diseases or conditions

Answer

No aid is offered to pharmaceutical companies for developing orphan drugs

Answer

Treatment of common disease in a resourceful country

Answer

Rifabutin is not an orphan drug

Question 4

Which of the following is not an alkaloid?

Accepted Answer

Aspirin

Answer

Physostigmine

Answer

Morphine

Answer

Atropine

Question 5

Which vitamin is known to inhibit wound healing?

Accepted Answer

Vitamin E

Answer

Vitamin A

Answer

Vitamin C

Answer

Vitamin B complex

Question 6

The H3 receptor agonist exhibits all of the following actions except:

Accepted Answer

Increase in H2 mediated gastric secretion

Answer

Inhibition of H1 mediated bronchoconstriction

Answer

Negative chronotropic effect on atria

Answer

Inhibition of H1 receptors induced wakefulness

Question 7

What is the primary mechanism by which steroids exert their anti-inflammatory action?

Accepted Answer

Phospholipase A2

Answer

Myeloperoxidase

Answer

Cyclooxygenase

Answer

Lipoxygenase

Question 8

At which phase of a drug trial is permission from the DCGI required?

Accepted Answer

Phase 1

Answer

Phase 2

Answer

Phase 3

Answer

Phase 4

Question 9

Therapeutic index of a drug is an indicator of its:

Accepted Answer

Safety Profile

Answer

Effectiveness

Answer

Adverse Effects

Answer

Therapeutic Effect

Question 10

Which of the following is NOT a primary function of histamine antagonists as a drug class?

Accepted Answer

Antivertigo

Answer

Antipruritic

Answer

Sedation

Answer

Inhibition of gastric acid secretion

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?